Surrozen (NASDAQ:SRZN) is a biotechnology company engaged in discovering and developing novel therapies aimed at regenerating tissues in the body. With a focus on leveraging the Wnt signaling pathway, a key regulator of tissue regeneration and repair, Surrozen is dedicated to addressing a wide range of diseases and conditions. The company's innovative approach involves creating bi-specific antibodies designed to selectively activate tissue repair in specific organs without affecting tissues elsewhere in the body. Surrozen's projects include developing treatments for liver diseases, inflammatory bowel disease, and various other conditions that currently have limited therapeutic options. The company's objective is to transform the landscape of regenerative medicine by offering new, more effective therapies that can promote organ regeneration and repair, thereby improving the quality of life for patients with debilitating diseases.